Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CSIB .0025x.0053 per IR 49M o/s 11/2/05
recent merger with a merchant banking subsidiary was made thru 1 yr restricted preferred shares so O/S will be low for awhile
10Q by the 15th...per bloomberg.com float is 22M
http://stockcharts.com/gallery/?csib
Universal Express Increases LEAP Territory Prices to $325,000
Wednesday November 2, 2:19 pm ET
http://stockcharts.com/gallery/?usxp
NEW YORK--(BUSINESS WIRE)--Nov. 2, 2005--Universal Express Inc. (OTCBB: USXP - News), today announced it will increase the Luggage Express Associate Program (LEAP) pricing. Increased pricing will take affect as of November 15, 2005 with a potential for increase of pricing again in January 2006.
"Despite a South Florida hurricane and 5 day loss of corporate electricity, over 33 requests to purchase LEAP territories (http://www.usxp.com/companies/universal/pr/prid.asp?id=359) for $250,000 have been received. We will honor those initial 33 applications if they close on their requested territories prior to November 15, 2005," said Keith Miller, LEAP Director.
"After November 15th and based on anticipated future national contract programs we will be increasing the territory costs to $325,000. Our next price increase is scheduled to be in January 2006, but may occur sooner," continued Robert Weiner, Director of Business Development.
"The LEAP program certainly has the potential of benefiting our initial 33 applicants beyond our software infrastructure, creative advertising, customer satisfaction, exceptional customer service, on-going training, and product expansion and development. On paper, their territory value has increased over $75,000 in less than 10 business day's average with or without electricity. That's a 'leap' no matter how one looks at it. The following states have had at least one territory requested; Texas (4 to date), Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Missouri, Mississippi, North Carolina, New Jersey, New York, Pennsylvania, South Carolina, Tennessee and Wisconsin," said Richard Altomare, CEO and Chairman of Universal Express, Inc.
"We're looking forward to the national development of Luggage Express through this innovative program. Imagine the value of a territory when all Americans consider separating themselves from their luggage and traveling without the burden of suitcases," concluded Cecilia Vesnesky, newly promoted Chief Operating Officer.
About Universal Express
Universal Express, Inc. is a 22 year old logistics and transportation conglomerate with multiple developing subsidiaries and services. For additional information please visit www.usxp.com
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Contact:
Universal Express, Inc.
Investor Relations
Keith Miller, 561-367-6177
kmiller@usxp.com
--------------------------------------------------------------------------------
Source: Universal Express Inc.
CSIB .0025x.003 49M O/S as of today per IR...recent merger was done thru 1 yr restricted preferred shares...business financing company....10Q coming by the 15th
DCUT .0001x.0002 company reduced float?
company seems to be lowering the float...as of yesterday, IR said the current float is 500M but checkout the previous count in pinksheets...
Float: 707,753,249 as of 2005-07-29
Float: 500,000,000 as of 2005-11-01 per IR
CMPN ShimodaAtlantic Xenavex compound is a more potent version of Anvirsel --Reports that slipped out in late 1999 showed that Anvirzel reversed AIDS, no matter what the phase of the disease, arthritis, psoriasis, hepatitis C, and even diabetes in some cases. Initially, Anvirzel was thought to work only on cancers found early, however, very positive results have been found in people given just weeks to live.
Anvirzel or Xenavex
"Anvirzel is a patented extract from the Nerium Oleander, a common house plant. [The plant is very toxic, however] the extract (Anvirzel) has been the twenty year study of a Dr Ozel from Turkey... Reports that slipped out in late 1999 showed that Anvirzel reversed AIDS, no matter what the phase of the disease, arthritis, psoriasis, hepatitis C, and even diabetes in some cases. Initially, Anvirzel was thought to work only on cancers found early, however, very positive results have been found in people given just weeks to live. To top this all off, Anvirzel seems to be the first cancer remedy to show positive results for leiomyosarcoma, probably the deadliest of cancers. Anvirzel also crosses the blood-brain barrier (like Poly-MVA) and gives hope to people with brain tumors."
Another drug from the oleander plant is called Xenavex (SAOB-0401) and is much more potent than Anvirzel. Anvirzel is made by Ozelle Pharmaceuticals, Inc., and Xenavex is made by ShimodaAtlantic Oncology Biosciences. I quote from an email to me from ShimodaAtlantic: "Drugs like Anvirzel and Xenavex should never be considered as "first line" options. The clinical experience of these drugs in cancer cases is virtually nil. Oleandrin is a potent cardioglycoside, similar in its mechanism of action to digoxin. This means that the drug has a great potential for harm, in addition to a potential for healing. A patient should consider such a drug only with the understanding that it is investigational; may result in no benefit; could cause a cardio-related adverse event, and that there may always be a better therapy option with experimental drugs that have a more robust clinical trial history."
To contact ShimodaAtlantic to see if you qualify for their Phase I / II study of SAOB-0401, in early 2005, in a non-small cell lung cancer, multicenter trial, and in a Phase I / II study in a small group of HIV/AIDS patients, their URL is: www.shimoda-atlantic.com
http://www.dsrct.com/oleander.htm
Contemporary Solutions Announces ShimodaAtlantic Launch of New Vertigo Drug Verticil
Monday , July 25, 2005 00:47 ET
LAS VEGAS, Jul 25, 2005 (BUSINESS WIRE) --Contemporary Solutions, Inc.(OTC:CMPN) announces that ShimodaAtlantic, Inc., a 20% subsidiary of Contemporary Solutions, Inc., is launching a new non-prescription vertigo drug: Verticil(TM).
ShimodaAtlantic(TM), Inc. of Las Vegas, Nevada, will begin deliveries to selected retail outlets of its new non-prescription oleander extract during the first week of August, 2005. The new item, retailing under the name Verticil(TM), will sell for $12.95, and is packaged in a 30ml (1 oz.) bottle with an integral dropper for dosage measurement.
The formulation of Verticil(TM), a liquid, is the maximum possible strength for a non-prescription oleander extract, according to company officials. The drug is made from organically grown oleander plants. It is intended for its labeled indication of vertigo.
Vertigo is a symptom, rather than a disease according to the National Institutes of Health (NIH), and affects 40% of the American population at least once in their lifetime. The principal active ingredient in Verticil(TM) is oleandrin. There are an additional 60 other naturally occurring substances in the extract.
ShimodaAtlantic(TM) also makes a prescription oleander-based drug, and is currently proceeding to clinical trials in the US to determine if the drug is effective against solid tumor cancers and certain viruses. The prescription version is marketed under the name Xenavex(TM). A series of scientific papers published by M.D. Anderson Cancer Center researchers since 2000 suggest that oleander extract may be an extremely effective anti-tumor agent. A May, 2005 study sponsored by the NIH study found that cardioglycosides like Xenavex(TM) may be effective in treating cystic fibrosis.
Verticil(TM) will also be available beginning in mid-August via an independent distributor's e-commerce and retail operation located in Bentonville, Arkansas.
ShimodaAtlantic is privately held. In June 2005, publicly-held Contemporary Solutions, Inc. (OTC:CMPN) purchased a 20% interest in ShimodaAtlantic, Inc. Verticil(TM), C-Trial(TM), and Xenavex(TM) are trademarks of ShimodaAtlantic, Inc.
This press release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Such statements can be identified by lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements, and changing price and market conditions.
SOURCE: Contemporary Solutions, Inc.
Princeton Research, Inc. (for Contemporary Solutions)
Mike King, 702-650-3000
or
ShimodaAtlantic, Inc.
www.shimoda-atlantic.com
310-401-6712, ext. 224
Copyright Business Wire 2005
CMPN - Contemporary Solutions, Inc. Acquires 20% Interest in Shimoda Atlantic, Inc.
Monday , June 13, 2005 00:21 ET
LAS VEGAS, Jun 13, 2005 (BUSINESS WIRE) --Contemporary Solutions, Inc. (OTC:CMPN) announced today that LEC Technologies, Inc., a wholly owned subsidiary of Contemporary Solutions, Inc., has acquired a 20% interest in Shimoda Atlantic, Inc., the parent company of ShimodaAtlantic Oncology Biosciences. SA's principal activities are in development of niche oncology pharmaceuticals. The Company plans a Phase II clinical trial of its drug Xenavex(TM) later this year, in non-small cell lung cancer patients.
Xenavex(TM) is a liquid pharmaceutical similar to digoxin, and is designed for daily oral administration. The drug is currently available as a federally controlled prescription item for its labeled indication of vertigo. Xenavex(TM) is manufactured from the leaves of the oleander shrub. The main active ingredient in the drug, oleandrin, has demonstrated significant anti-tumor activity during in-vitro evaluations, according to a series of peer-reviewed papers published by University of Texas researchers since 1999. A recent study sponsored by the National Institutes of Health suggests that a small group of cardioglycosides including oleandrin, mimic "gene therapy" in cystic fibrosis cases. Xenavex has been approved by the FDA, in isolated cases, for "compassionate use" by cancer patients seeking access to it as a "drug of last resort."
In the agreement with LEC Technologies, Shimoda receives cash, stock options in LEC Technologies, Inc., and Contemporary Solutions agrees to commercialize and market ShimodaAtlantic's "C-Trial(TM)" clinical trials database solution. C-Trial(TM) is a scalable, menu driven database manager oriented toward all phases of FDA clinical trials. It features fillable "Case Report Forms (CRF's)" and allows study-site clinicians to quickly report and then locally assess their own patient data. The system also allows a study sponsor to remotely access the study-site database, and retrieve data in real-time, and merge it with the data from other study sites. That process allows study managers to make daily assessments of all aspects of the clinical trial process, and provides an extra margin of patient safety.
C-Trial and Xenavex(TM) are trademarks of Shimoda Atlantic, Inc.
This press release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Such statements can be identified by lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements, and changing price and market conditions.
SOURCE: Contemporary Solutions, Inc.
Princeton Research, Inc.
Mike King, 702-650-3000
or
Shimoda Atlantic, Inc.
310-401-6712, ext. 224
Copyright Business Wire 2005
CMPN .003x.005 cheapest pharma with two FDA approved drugs Xenavex and Verticil 13M float per yahoo finance...watch it
per IR as of today, 11/2/05 ..49M o/s ..merger completed thru issuance of 1 yr restricted preferred shares
500K investment in BICO is secured
EQUR AFTER HOUR NEWS..GOLDEN CROSS PENDING http://stockcharts.com/gallery/?EQUR
Equus Resources Plans to Acquire Interest in Community Bank
Tuesday November 1, 5:00 pm ET
ATLANTA, GA--(MARKET WIRE)--Nov 1, 2005 -- Equus Resources, Inc. (Other OTC:EQUR.PK - News) ("Equus") today announced it intends to acquire an equity interest in a community bank in a growth area in Georgia. To help it achieve this goal, Equus has engaged the services of Stevens & Company, a Georgia-based community banking merger and acquisition specialist. Over the past five years, Stevens has been part of 52 community bank merger/acquisition transactions in the southeastern United States, primarily Georgia. Stevens has also participated in creating markets for various community bank stocks. Stevens has already identified for Equus a Georgia bank available for acquisition and the Equus principals hope to commence acquisition negotiations with this candidate next week.
ADVERTISEMENT
In making this important announcement, Bert Watson, Equus CEO, commented: "Our objective in seeking an equity position in a community bank is twofold: (1) to use our collective knowledge, experience, contacts and talents to help expand the bank's deposits, assets and lending capabilities, leading to a healthy increase in its overall value, and (2) to develop a strong strategic relationship between Equus and the bank which will benefit both entities by enabling them to cross-market to their respective consumer and commercial clients a much broader array of financial and banking products and services. We believe that such a synergistic commercial banking alliance will be hugely beneficial to Equus as we continue to implement its growth plans and, consequently, we have launched a full-court press to find the right bank, right now."
About Equus Resources
Equus Resources is a diversified financial services company that offers its consumer and commercial clients a broad range of products and services, mainly in the southeastern states. Equus plans to expand its core business through internal growth and acquisition and to add related lines of business as demand warrants. Equus is headquartered in Roswell, Georgia, a suburb of Atlanta. For more information, please visit us at www.equusresources.com or e-mail us at investorinfo@equusresources.com so we can add you to our electronic mailing list.
Forward-Looking Statements:
Any statements made in this press release which are not historical facts contain certain "forward-looking statements," as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the Company to which this release pertains. The actual results of the specific items described in this release, and the Company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgment of management of the Company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties, including, without limitation, the Company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, the receipt of revenues, and other factors, many of which are beyond the control of the Company.
Contact:
Contact:
Randy Harris
Ph: (678) 467-3730
--------------------------------------------------------------------------------
Source: Equus Resources, Inc.
DCUT CONTACT INFO For further information contact Pierre Quilliam or Jeff Kompon, #941-761-7848 and/or Rich Kaiser, Investor Relations, YES INTERNATIONAL, #800-631-8127
DCUT .0001 x .0002 500M FLOAT ..IR SAYS THEY PLAN TO BE FULLY REPORTING AGAIN
SYCI .012x.0126 bullish macd crossover
http://stockcharts.com/gallery/?SYCI
PABN .0002X.0003 GOLDEN CROSS SOON SEE CHART
http://stockcharts.com/gallery/?PABN
DCUT .0001X.0002 biometry, networks ..watch it...finally off the shorted list since Oct 28
PYPR .0003 350M float..it seems movable especially with $5.2M annual revenues and net income...closed above the 50 day moving average last week
http://stockcharts.com/gallery/?pypr
PABN .0002 golden cross coming..check the chart
http://stockcharts.com/gallery/?pabn
PMHJ .0003x.0005 changing business direction to oil and natural gas play...could be the next IDCN...Target Communication dividends are still pending
http://stockcharts.com/gallery/?pmhj
PABN .0002x.0003 golden cross seems be heading its way..check the chart for the cheapest bank around
http://stockcharts.com/gallery/?pabn
SYCI .012 x .0136 uptick...chart looking better for a 15M o/s acquisition play
http://stockcharts.com/gallery/?syci
SYCI .01 15M o/s acquisition play..nice chart
http://stockcharts.com/gallery/?syci
Hi guys..I've been watching this board for quite sometime now
checkout some of these stocks
EQUR previous pick of RUliquid...I've been holding it since subpenny...in 2004 mortgage division originated $70M in loans...pending acquisition of a bank and the chart is a screaming golden cross
http://stockcharts.com/gallery/?equr
CMPN .003 x .005 acquisition play...already owns 20% of ShimodaAtlantic pharma company which has a prescription drug Xenavex - the compound was reported to reverse aids, hepatitis c, psoriasis, cancer etc and will be in clinical trials ..another overthecounter drug Verticil was launched for vertigo recently
http://stockcharts.com/gallery/?cmpn
CSIB .006 x .01 is a business financing company ..49M o/s...they already own controlling interest in Bio-One and recently funded PWTC...nice golden cross soon
http://stockcharts.com/gallery/?csib
TRIT ask at .004 is a shell play....I called the phone indicated at pinksheets.com and got a hold of the contact person...165M o/s 90% owned by insiders, acquisitions have taken place, shell was purchased for acquisitions, news to come soon
http://stockcharts.com/gallery/?trit
PABN .0002 ..according to knobias.com, PABN is Panamerican Bank, a subsidiary of an AMEX stock PNB Panamerican Bancorp which has $250M in assets...for the first time in 5 years, a PR was issued last June...maybe some good things to come on valuations
http://stockcharts.com/gallery/?pabn
PYPR .0003 according to their financials has $5.2M in revenues plus NET INCOME...check the chart
http://stockcharts.com/gallery/?pypr
more to come....